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Bacteriophages (phages), discovered 100 years ago, are able to infect and destroy only
bacterial cells. In the current crisis of antibiotic efficacy, phage therapy is considered
as a supplementary or even alternative therapeutic approach. Evolution of multidrug-
resistant and pandrug-resistant bacterial strains poses a real threat, so it is extremely
important to have the possibility to isolate new phages for therapeutic purposes. Our
phage laboratory and therapy center has extensive experience with phage isolation,
characterization, and therapeutic application. In this article we present current progress
in bacteriophages isolation and use for therapeutic purposes, our experience in this
field and its practical implications for phage therapy. We attempt to summarize the
state of the art: properties of phages, the methods for their isolation, criteria of phage
selection for therapeutic purposes and limitations of their use. Perspectives for the use of
genetically engineered phages to specifically target bacterial virulence-associated genes
are also briefly presented.
Keywords: bacteriophage isolation, therapeutic phages, experimental phage therapy, treatment of bacterial
infections, antibiotic resistance
INTRODUCTION
The post-antibiotic era in which minor injuries and common infections can kill – because of
lack of drugs or their ineffectiveness – nowadays is not an apocalyptic fantasy, but a real 21st
century possible threat (WHO, 2014). For example, ESKAPE organisms (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter species) are extremely resistant to multiple antimicrobial agents (Moellering,
2010) and are a serious challenge in medicine today.
According to the National Institutes of Health (NIH, USA), phages are innovative components
that may be used to combat microbial resistance (NIH, 2014). Clinical application of phage
preparations is associated with well-described and -characterized processing, and its influence on
phage stability during preparation and under storage conditions should be verified and described
in detail, especially as it is needed for phase III clinical trials (Vandenheuvel et al., 2015). As
suggested, personalized phage therapy is probably more effective than prêt-à-porter preparations,
as it is based on tailored preparations which can be adjusted to changing bacterial pathogens (Keen,
2012; Mattila et al., 2015).
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STATE OF THE ART
Bacteriophages are viruses which have the ability to multiply
only in bacterial cells, and they are detectable almost everywhere
where live bacteria exist (they have been isolated from all
environments and ecological niches, e.g., inland waters, hot
springs, salt water, soil, cold water) (Lin et al., 2010; Zheng et al.,
2013; Zhan et al., 2015). It is estimated that in the biosphere there
are approximately 1030−31 phages (Hendrix et al., 1999; Hendrix,
2002), which is 10-fold higher than the total number of bacterial
cells (Abedon et al., 2011a). They are an inherent element of the
human microbiome, and therefore they are well tolerated when
used in phage therapy (Mie˛dzybrodzki et al., 2012; Reyes et al.,
2012).
A serious medical and social problem results from the
increasing antibiotic resistance of bacterial strains (Arias and
Murray, 2009; Magiorakos et al., 2012; Deris et al., 2013; WHO,
2014). The pharmaceutical industry is withdrawing from research
and development on new antibiotics due to unprofitability of the
venture and the risks of development of resistance in bacteria
(Clarke, 2003).
Initially, bacteriophages were isolated from stool samples of
patients suffering from diarrhea and were first successfully used
in the treatment of bacterial dysentery (D’Hérelle, 1917). Hankin
was the first to observe that the water of the Ganga and the
Yamuna rivers (India) had antiseptic properties; in particular,
water samples from them were able to destroy Vibrio cholerae
(Hankin, 1896; Abedon et al., 2011b).
In humans phages have been successfully used in the treatment
of a wide range of infections, both local and systemic (Weber-
Da˛browska et al., 2001, 2003; Borysowski and Górski, 2008;
Mie˛dzybrodzki et al., 2012; Borysowski et al., 2014; Rose et al.,
2014). This is due to the fact that they have many features which
give them advantages over antibiotics, e.g., phages multiplying
at the site of infection where there are bacteria sensitive to
them (Abedon and Thomas-Abedon, 2010; Loc-Carrillo and
Abedon, 2011; Kutter et al., 2012). Interestingly, development
of the resistance of bacteria to antibiotics does not parallel
the development of phage resistance in bacteria, although the
acquisition of resistance to phages by bacteria may pose a
significant problem (Loc-Carrillo and Abedon, 2011). Therefore,
as mentioned, phages can be used to treat infections caused by
antibiotic-resistant bacterial strains (Górski et al., 2007; Kutter
et al., 2010), including bacteria resistant to multiple antibiotics
(Górski et al., 2007; Hanlon, 2007). Moreover, it has been
demonstrated that phage therapy is safe and relatively free of side
effects (Borysowski and Górski, 2008; Łusiak-Szelachowska et al.,
2014; Jon´czyk-Matysiak et al., 2015).
The use of bacteriophages in antimicrobial phage therapy is
based on their ability to recognize, adsorb and multiply only
within the bacterial cell and cause its lysis (Burrowes et al., 2011).
Phage therapy is defined as the use of bacteria-specific viruses to
combat pathogenic bacteria that cause infections (Loc-Carrillo
and Abedon, 2011). Bacteriophages are usually highly specific
and may be active against antibiotic resistant Gram-positive and
Gram-negative bacteria (Biswas et al., 2002; Burrowes et al., 2011;
Vinodkumar Srinivasa et al., 2011; Chhibber et al., 2013).
Phages have been used as a therapeutic agent in two main
centers (Weber-Da˛browska et al., 2000a,b; Sulakvelidze et al.,
2001; Clark and March, 2006): in Poland [the Ludwik Hirszfeld
Institute of Immunology and Experimental Therapy, Polish
Academy of Sciences in Wroclaw (IIET PAS)] and at the Eliava
Institute in Tbilisi, Georgia. In 2005 the Phage Therapy Unit
was opened there – the first of its type in the European Union.
Over the past few years, phage therapy has gained wider interest
(Denou et al., 2009; Górski et al., 2009, 2012; Mie˛dzybrodzki et al.,
2012; Pirnay et al., 2012; Henein, 2013; McCallin et al., 2013;
Borysowski et al., 2014; Matsuzaki et al., 2014). Moreover phages
are used as therapeutics also, e.g., in former USSR and the Russian
Federation (Krylov et al., 2012; Krylov, 2014; Sarker et al., 2016).
SOURCES OF PHAGE ISOLATION AND
PHAGE PROPAGATION HOSTS
The environment is a unique source of all types of phages,
offering the possibility to isolate them for therapeutic purposes
(Naghavi et al., 2013; Shukla et al., 2014). Phages are unevenly
distributed, with the prime source of phages against human
bacterial pathogens being the immediate hospital vicinity (Latz
et al., 2016). For quality controlled production, phages active
against P. aeruginosa and S. aureus were isolated from sewage
and river water (Merabishvili et al., 2009). Already Dubos
et al. (1943) isolated phages against Shigella dysenteriae 2308
from New York city sewage. The isolation of phages from
environmental sources is more often possible when the sample
contains the target bacterium (Gill and Young, 2011; Periasamy
and Sundaram, 2013). An optimal source for searching for new
phages is sewage (Łobocka et al., 2014; Weber-Da˛browska et al.,
2014). Vandersteegen et al. (2013) isolated raw inlet sewage water
phages, Romulus and Remus, active against S. aureus. These
phages infected 80% of tested strains and had the potential to
destroy biofilm. It is also possible to obtain new virulent phages
from stream water (Ul Haq et al., 2011). Sheep and cattle fecal
samples were also a source of newly isolated phages.
The occurrence of phages against bacteria that are not
abundant, in samples obtained from the environment, is usually
low, so the simplest and most direct methods for their
isolation may be unreliable. Therefore it is recommended to use
large volume sample because concentration and/or enrichment
methods may be relevant (Gill and Young, 2011). In larger
sample volumes the possibility to detect phage is increased,
and this type of searching may be recommended when too few
desired phages are present in the sample (Gill and Hyman, 2010).
Sometimes phage inactivation may occur during the waste water
treatment process; e.g., during anaerobic-aerobic adsorption
on solid particles as well as aerobic treatment using activated
sludge or flocculants (Tanji et al., 2002). But, in Bacteriophage
Laboratory IITD PAS phages active against Enterococcus and
Staphylococcus strains were isolated from drinking water (Weber-
Da˛browska et al., 2014).
The broad host range phage isolation protocol from sewage
and pond water was described by Jensen et al. (1998). The widely
considered narrow host range of isolated phages may be the result
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of the isolation procedure rather than the naturally occurring
phage spectrum. Host specificity of phages that are isolated from
aquatic samples is broader than that of phages isolated from
other types of samples (Wommack and Colwell, 2000). Two
staphylococcal phages, PhiSA039 and PhiSA012, isolated from a
municipal wastewater treatment plant in Tokyo were shown to
have a wide host range (Synnott et al., 2009). Similarly, the P-
27/HP bacteriophage isolated from sewage was polyvalent and
was able to control multidrug resistant S. aureus (Gupta and
Prasad, 2011). It was able to kill 60% of isolates of S. aureus
from humans. Parra and Robeson (2016) found three polyvalent
bacteriophages (FC, FP, and FQ) infecting the S. enterica serovar
Choleraesuis and Escherichia coli strains, in wastewater samples
in Chile. Yu et al. (2015) suggested that polyvalent phages may
be rapidly isolated from the environment by using different
sequential hosts. Their novel method is based on two sequential
multihost isolations, and both culture-dependent and culture-
independent phage libraries were tested for phages of broad range
of infectivity. These methods were found to be useful for isolation
of broadly polyvalent phages that were able to infect bacteria
of distantly related taxons. Another example of unexpectedly
broad host-range phage is phage JHP, which was isolated recently
by Khawaja et al. (2016). Unfortunately, it is difficult to obtain
phages whose specificity is broad enough to cover all strains
within a pathogenic species, despite the fact that it is possible to
isolate phages with a broad host range (Nilsson, 2014). A typical
problem in phage therapy is a narrow host-range of certain
phages. T4 phages tested by Denou et al. (2009) for the efficacy
in curing E. coli diarrhea proved to be not only species- but
also strain-specific. Therefore, it was necessary to use phage
cocktails containing 10 and 16 phages that cover half to two
thirds of E. coli strains (representing the five main pathotypes
isolated from patients suffering from diarrhea). Ready-made,
broad-host-range cocktails that contain phages active against
different pathogens may be a good solution when rapid phage
application is needed.
The richest source of the most effective therapeutic phages
is the material from patients who recovered from an infection
(D’Herelle, 1938). Mattila et al. (2015) isolated phages on
demand from sewage. They emphasized the ease of isolation
of phages against such pathogenic strains as Pseudomonas
aeruginosa, Salmonella, extended spectra beta-lactamase E. coli,
and K. pneumonia, but greater difficulty to find phages active
against vancomycin-resistant Enterococcus and Acinetobacter
baumannii strains. Isolation of phages that are active against
S. aureus turned out to be the most difficult. However, e.g.,
Kwiatek et al. (2012) and Sahin et al. (2013) obtained phages
active against S. aureus clinical MRSA strains.
O’Flynn et al. (2004) isolated phages active against the
E. coli O157:H7 strain from human fecal samples of patients
with gastrointestinal disorders, and from bovine feces. Certain
phages were isolated from human skin swabs, in particular from
bacterial strains (Brown et al., 2016), e.g., phages specific to
Propionibacterium acnes. Raw hospital sewage samples were the
source of the phiAxp-3 lytic phage which was active against
Achromobacter xylosoxidans A22732 (Ma et al., 2016). This phage
was active against four A. xylosoxidans strains tested.
Sometimes, it is possible to isolate a phage against certain
strain of pathogenic species and then adapt this phage to another
host strain against which one cannot easily isolate new phages.
Typically, high titer lysates containing phages that can
effectively infect certain strains of bacterial pathogens can be
obtained by the propagation of these phages in cells of related
strains. Sometimes, to avoid the risk of infection and to simplify
the culture procedure, a non-pathogenic bacterial strain – called
a surrogate strain – may be chosen for phage isolation and
propagation (Gill and Hyman, 2010). For example, David et al.
(1980) chose for their research Mycobacterium smegmatis – a
species safer than the closely related pathogenic M. tuberculosis –
to propagate the D29 phage. This strain grew rapidly compared
to the pathogenic M. tuberculosis and was also susceptible to the
D29 phage; therefore for practical reasons it was chosen for the
propagation of this phage.
SYNERGY BETWEEN PHAGES
Some phage preparations are in the form of a cocktail – they
may be composed of more than one phage. Phages in the cocktail
may be active against various strains of the same bacterial species,
but the killing of target bacteria by the cocktail may be more
effective than expected based on the lytic activities of single
cocktail phages. This phenomenon is referred to as synergy, and
it may be helpful and useful from the therapeutic point of view.
According to research conducted by Schmerer et al. (2014), it
is possible to obtain such synergy if one phage can facilitate the
infection of the same bacterium by another phage. They isolated
the phage from sewage and observed that it caused the formation
of large plaques on a mucoid E. coli strain. The large size of
plaques resulted from the combined activity of two phages – J8-
65 (turbid plaques with a halo effect) and T7 (forming small
plaques). The combination of these two phages resulted in 10–
100-fold higher killing efficacy of host bacteria compared to each
phage alone. The likely cause of this synergy was the activity of J8–
65 colanidase - an enzyme which degrades the exopolysaccharide
of mucoid bacterial surface. By degrading a mucoid barrier
protecting cells from the T7 adsorption, the colanidase provided
easier access of T7 to the bacterial cell surface receptors. This
observed synergy was temperature- and media-dependent. From
a practical point of view, phage-encoded depolymerase enzymes
may facilitate phage access to bacteria in a biofilm community
(Cornelissen et al., 2011; Pires et al., 2016), which may have
practical implications in biofilm treatment. Phage efficacy in
destroying biofilm was observed in the case of biofilms formed by,
e.g., Enterococcus or Staphylococcus (Gutiérrez et al., 2015; Khalifa
et al., 2015).
The knowledge based on the possibility to obtain synergy may
significantly improve production of phage preparations intended
for phage therapy, as it strengthens their potential efficiency.
METHODS OF PHAGE ISOLATION
Samples that are believed to contain phages may be directly –
after sterilization by filtration (0.22 µm) or after incubation
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(enrichment method) – plated on a bacterial host lawn to
search for plaques – the simplest method for visualization of
phage occurrence. It is worth considering that for each phage
and bacterium specific medium, growth and storage conditions
should be adjusted and evaluated (Fortier and Moineau, 2009).
Moreover, for new phage isolation it is recommended to use one
bacterium in the exponential phase of growth (Wommack and
Colwell, 2000; Kutter, 2009). To verify the findings, each test
should be performed at least in duplicate.
Liquid samples seem to be easier for phage searching, whereas
solid ones need to be suspended in a sterile liquid medium.
Sometimes it is possible to use pooled samples (e.g., in searching
for phages in the urine of an infected patient, when the material
was collected at different time points). However, independent
testing seems to be a more likely method of isolating phages
than pooling (Gill and Hyman, 2010). The main steps in phage
isolation for therapeutic purposes are presented in Figure 1.
Identification of new phages and adding them to the collection
begins with multiplying phages obtained from an environmental
sample with the use of the target bacterial host and checking the
activity of the phage against strains of a well-defined bacterial
collection. This procedure is known as the determination of the
phage host range on a target host strain panel (Mirzaei and
Nilsson, 2015; Pirnay et al., 2015). Interestingly, some phages
can form plaques that are too small to be seen. An example is
Bacillus phage G, which cannot diffuse through agar, due to its
extraordinary large virion size (Hendrix, 2008).
There are many ways to improve the visibility of phage
plaques on a bacterial lawn. One possible method, especially
in the case of phages isolated from environmental samples, is
the use of sublethal doses of antibiotics (e.g., 2.5–3.5 µg/ml of
ampicillin, depending on the top agar thickness), which was
suggested by Łos´ et al. (2008). This allows one to obtain plaques
of increased diameter or obtain any kind of visible plaques in
standard conditions in the case of E. coli phages. Similarly, Kaur
et al. (2012) also used sublethal doses of antibiotics (inhibitors
of proteins synthesis) to increase the size of MR-5 phage plaques
(which are usually tiny, small, and difficult to visualize) on
the methicillin-resistant S. aureus strain. The addition to the
soft agar layer of 2,3,5-triphenyltetrazolium, sodium thiosulfate
or ferric ammonium citrate, as it was done in the case of
Salmonella enterica subsp. enterica bacteriophages isolated from
swine lagoon eﬄuent may be another way to facilitate plaque
visualization (McLaughlin and Balaa, 2006).
For therapeutic purposes it is necessary to select a phage
against the isolated bacterium that is the cause of infection. There
may be a large number of phages in the tested sample, but only
one may be identified on a particular bacterial strain lawn (Kutter,
2009).
When multiple phages are expected to be present in a tested
sample, the enrichment method is used with more than one
bacterium, and the obtained cell lysate may potentially be a source
of many phages (Łobocka et al., 2014). In this method bacteria
are usually cultivated in LB medium or in broth, sometimes
in BHI broth (Beheshti Maal et al., 2015). D’Herelle (1938)
recommended applying more than 50 bacterial strains in this
procedure. One may even use bacteria from different taxons
(genera, species) and obtain phages with a wide host range
(Łobocka et al., 2014).
Liquid culture and the solid plate method are preferred for
phage isolation. The double layer method is used to determine
the titer of phage in the sample and/or preparation at each step of
searching and preparing phage preparations used as therapeutics
(Gratia, 1936; Adams, 1959). Fresh bacterial culture in the
expotential phase of growth is mixed with the environmental
sample sterilized by filtration (where phages are likely to be
detected) and incubated properly depending on the host bacterial
strain, to allow the phage to amplify and attain a high titer.
If a plaque is observed on the bacterial lawn, the next step of
phage isolation is to pick and transfer a single plaque into liquid
medium (Mattila et al., 2015). The efficiency of plating (EOP) of
some phages, e.g., the T4 phage, is 100%, which means that in
optimal conditions every single particle of the phage can infect a
host cell and produce plaques (Kutter, 2009). Typically, three to
five passages are necessary to ensure the multiplication of a single
phage from the environmental sample (Łobocka et al., 2014).
The monoclonality of phage preparations is a separate issue, as
commonly used phage propagation strains may be a source of
contaminating undesired phages.
To detect the presence of phages in samples in which we could
not detect them using the plate method, the colorimetric method
is used in our laboratory (Figure 1). It is simple and sensitive,
and it offers unequivocal results (McLaughlin, 2007; Z˙aczek et al.,
2011). It exploits the ability of living bacterial cells to reduce the
tetrazolium to formazan, which is visible as the appearance of a
dark red color in the bacterial culture over time. Lysis of bacteria
results in the lack of culture medium staining as compared to
the control and may suggest the presence of phages in the tested
samples. Advantages of this method include the possibility to
detect phage particles present in the sample in a low number
and the possibility to detect phage presence in many samples
simultaneously during one experiment. Fischer et al. (2013) also
recommended the microplate test for the rapid determination of
bacteriophage susceptibility of Campylobacter strains. Moreover
this method is suitable for automation of the phage susceptibility
testing. Additionally, the microplate test allows one to examine
a 5–10-fold greater number of isolated strains, compared to the
conventional plate method.
A method that is useful for the acquisition of phages for
cocktails with great therapeutic potential is so called step-by-step
(SBS) method (Gu et al., 2012). It is based on the selection of lytic
phages active against both the wild type phage-sensitive strain
and its phage-resistant variant. The wild type bacteria and the
first phage-resistant strain are used for isolation of the first and
the second phage, and bacteria resistant to the second phage are
applied to isolate the third phage.
Mirzaei and Nilsson (2015) compared the efficiency of plating
(EOP) and host range of several phages using the spot test and
the double-layer agar method that are commonly used in the
initial phage characterization. Strains of the standard E. coli
and Salmonella reference collections, and ESBL-producing E. coli
served them to isolate phages from sewage water and waste water
from Stockholm (including hospital samples). Six phages of the
widest lytic spectrum were chosen for the comparative analysis
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FIGURE 1 | Steps in phage isolation for therapeutic purposes.
of both methods. The results did not fully correlate. The authors
suggested that the differences may be an effect of lysis from
without, the presence of bacteriocins or endolysins in the lysate,
or the presence in certain bacterial strains of prophages encoding
phage resistance genes.
Most often, phage growth in laboratory conditions does
not reflect its good propagation in vivo (Weld et al., 2004).
Phages that have similar properties and may have a similar
host range under laboratory conditions can have different
therapeutic efficacy in vivo. Therefore, it is important to select
for therapeutic purposes only phages that have high fitness
in vitro, and try to simulate conditions corresponding to the
site of infection to check phage potential therapeutic efficacy
(Bull et al., 2010; Bull and Gill, 2014; Łobocka et al., 2014). It
is believed that phage success in therapeutic application may
result from appropriate phage-bacterial dynamics (Bull and Gill,
2014).
For phage screening it is recommended to use as many
bacterial strains as possible. Phage typing and the host range
are usually determined using a routine spot test, in which
phage lysates or their dilutions are used. This method is
simple, quick and not expensive, yet very useful, and it gives
an overview of the bacterial sensitivity to a particular set of
phages.
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THERAPEUTIC PHAGES
The most common phage preparations are colloid suspensions
(protein based), most often prepared freshly (Vandenheuvel
et al., 2015). For therapeutic purposes bacteriophages should be
dispersed in solution, stable, safe and have a high affinity to
bacteria. Thus, lytic tailed phages belonging to the Myoviridae,
Siphoviridae, and Podoviridae families are used for phage therapy
(Wittebole et al., 2014).
The historical collection of Bacteriophages in the IIET PAS was
initiated by Ludwik Hirszfeld, who was working with Salmonella
bacteriophages. Currently, the collection contains approximately
800 phages, active against mainly such pathogens as Escherichia,
Morganella, Klebsiella, Enterobacter, Enterococcus, Pseudomonas,
Staphylococcus, and Salmonella, and it is being continuously
expanded. In the collection there are phages that were isolated
from hospital sewage, inland and marine waters, animal and
human feces, water, soil, plant, and clinical materials, e.g., from
patients with the diabetic foot syndrome. Our phage collection
contains phages that may be active against both K. pneumonia
PDR (resistant to carbapenems), E. coli O157:H7 and O104:H4
(which caused the death of more than 50 patients in Germany in
2011). The procedure of preparing phages against S. aureus and
P. aeruginosa has been in our laboratory under patent protection
since 2002 (EP1 406 642 B1, PL 19543781, US 7, 232564 B2).
We noticed that phages in our collection have wide lytic
spectra. The ones with the widest spectrum are staphylococcal
phages (mean = 95%); coliphages have mean activity against
E. coli strains of 86% (including ESBL-positive strains); E. faecalis
phages destroy approximately 80% of our strains; phages active
against Klebsiella lyse 62% of our strains; whereas P. aeruginosa
phages lyse 56%. In the case of some Salmonella serotypes we
have phages with activity as high as 100%. We found that newly
isolated bacterial strains are less sensitive to “historical” phages.
This phenomenon has been observed especially in the case of
E. coli, K. pneumonia, P. aeruginosa, and, on a lesser scale, in the
case of S. aureus strains.
It is recommended to maintain ongoing monitoring of
available phage collections and update phage cocktails with
newly isolated and characterized phages, removing old and
inactive ones (Gill and Young, 2011). Our laboratory’s phage
collection increases constantly with phages isolated from both
environmental and clinical materials. There is a possibility as well
to use a preparation from our repository and quickly apply it in
a patient (Fortuna et al., 2008). Even when phage sensitivity is
changing during phage therapy, it is possible to find a new active
phage.
Plaque morphology is important for the selection of
therapeutic phages. Only clear, non-turbid plaques without a halo
effect should be classified as the effect of the lytic phage activity.
The obtained plaques are a complex result of different phage
features, growth phase of the bacterial host, diffusion of virions in
agar plate, and inactivation of phage particles by debris of bacteria
(Abedon and Yin, 2009; Gill and Young, 2011). Similarities
in morphology between plaques may often result from similar
properties of phages that infect related bacteria. Phage adsorption
from the therapeutic point of view is effective when it is fast –
typically 70% or higher in 10 minutes. According to Bull and Gill
(2014), it is possible to predict phage success when the phage-
bacterial population dynamics is known. Successful treatment
requires phages of high lytic activity – a feature that is correlated
with the phage burst size (Mirzaei and Nilsson, 2015).
After phage isolation it is necessary to characterize every new
phage before incorporating it into the collection. It is important
to test: the latent period, the burst size (Hyman and Abedon,
2009; Mirzaei and Nilsson, 2015), host growth, “phage lifestyle”,
the adsorption rate, multiplicity of infection (MOI), and stability
in storage condition, morphology of plaques, phage morphology,
ultrastructure, and taxonomy (Ackermann and Heldal, 2010; Gill
and Hyman, 2010). Moreover, phages should be characterized
by sequencing of the whole genome to exclude toxin genes,
virulence factor genes, and genes responsible for lysogeny, and
they should have low transducing potential (Łobocka et al.,
2014). For the safety of phage application it is also necessary
to remove prophages and certain other mobile genetic elements
from phage propagation strains. The risk of, e.g., virulence genes’
presence in phage genomes cannot be totally excluded for safety
reasons (Vandenheuvel et al., 2015). So, every single isolate
should be considered as an entity with individual properties
and requirements. Quality requirements for the production of
phage preparation intermediate or finished products should be
provided in laboratories with specified air quality and cleanliness,
which minimize the risk of its contamination, and the biosafety
level depends on the type of bacteria that are used in preparing
formulations (Pirnay et al., 2015).
The requirement for manufacturing the BFC-1 phage cocktail
for clinical trials using good manufacturing practices (GMPs) was
obvious (Merabishvili et al., 2009). All products that are used for
the preparation of the cocktail were certified. The preparation
was cleared of endotoxins. Pirnay et al. (2015) the quality and
safety requirements for sustainable phage therapy products were
published. They suggested that manufacture of products for
phage therapy should be described in detail at each stage of the
process in standard operating procedures (SOPs) and validated.
CRITERIA OF PHAGE SELECTION FOR
THERAPEUTIC PURPOSES
Phage Properties
The most important criterion for selecting phages for therapeutic
application is their specificity – called affinity (Ly-Chatain,
2014). This property is of great importance for phage therapy.
Therefore, one should be certain that an isolated bacterium is
sensitive to the selected phage, as it may limit the effectiveness of
phage application (the use of preparations such as cocktails may
improve phages’ lytic spectrum) (Goodridge, 2010). To manage
the problem associated with phage specificity it is advisable to use
phage cocktails which have broader lytic activity against bacteria
than single phages. Phages with broad spectrum-strain lytic
activity should be selected. Phage specificity for certain species of
Gram-positive and Gram-negative bacteria (including antibiotic-
resistant strains, e.g., MRSA, VRE, ESBL-producing E. coli,
and multidrug resistant P. aeruginosa) allows one to eliminate
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pathogenic bacteria without affecting the natural microflora.
There are suggestions that some phages show family rather than
genus or species specificity (Gill and Hyman, 2010).
There are numerous criteria that allow us to classify phages
as useful for therapeutic purposes, including efficacy of phage
therapy and the possibility to avoid adverse effects (Denou
et al., 2009). First of all it is postulated to use only lytic
phages. Temperate phages often give visibly turbid plaques
(Gill and Young, 2011). According to Ackermann (2005), it is
estimated that approximately half of the phages isolated from
the environment are temperate. It is important for consideration,
because most therapeutic phages are isolated from environmental
samples. The presence of prophages within a bacterial strain
may cause lysogenic conversion, which undermines phage
applicability in therapy. Therefore, phages that contain genes
for lytic phage repressors, integrases or transposases should
not be used for therapeutic purposes (Łobocka et al., 2014). It
is especially important, because certain mutants of temperate
phages may cause the formation of clear plaques (Weigle, 1953).
For safety reasons, every phage that has potential for
therapeutic application should be sequenced. Especially the
possibility of phage genome participation in horizontal gene
transfer should be investigated (Pirnay et al., 2015; Davies et al.,
2016). Phages have not been demonstrated to have adverse effects
on eukaryotic cells, and they should be safe for humans and
animals.
Phage Stability under Storage
Conditions and Formulations
Phages are composed of protein structures, and therefore they
may be instable in solution form (Vandenheuvel et al., 2015).
It is recommended to adjust the type of storage of phages to
their biology and properties. Most often, the best way of their
storage is cooling. Sometimes it is possible to add substances that
may enhance phage stability in water suspension, or to preserve
by freeze-drying, spray drying, or encapsulation. Some phages
are considered as stable when their titer does not significantly
decrease for a few days, while others preserve their stability
for years. In the case of preparations applied for therapeutic
purposes, there are quality and safety requirements that storage
conditions should be validated and monitored (Pirnay et al.,
2015).
Phage storage should assure the stability of phage particles
in the form and conditions in which the preparation is stored,
but the form of application should also protect phage particles
against losing their activity. For example, Cooper et al. (2014)
tested a cocktail of three phages (phages GL-1, GL-12.5, and
LP-M10) active against P. aeruginosa in the form intended for
nebulized formulation. The assessed phages retained their activity
over 180 days at a storage temperature of 4◦C as well as at room
temperature, and they were successfully nebulized with little loss
of infectivity. However, the endotoxin levels [as verified by the
Limulus amoebocyte lysate (LAL) test] were considerably higher
than the acceptable levels.
Phage particles’ stability in a preparation intended to be
used in humans may depend on the composition of the
phage preparation. O’Flaherty et al. (2005) observed that the
K phage active against S. aureus showed stability in bismuth-
based cream and this cream exhibited bactericidal activity also
several days after storage at room temperature. What is more,
in a semi-solid preparation – a Cetomacrogol cream – at a
concentration of 2.5 × 108 pfu/ml per gram, Propionibacterium
acnes phages remained active for 90 days when the preparation
was stored at 4◦C in a light-protected place (Brown et al.,
2016). A non-ionic cream base preparation was chosen because
it excludes potential occurrence of interactions of ions with
phage particles. These properties, especially stability and its
easy-to-use form, assure this preparation’s potential for topical
treatment of acne infection. Esteban et al. (2014) stabilized
the K-phage and delivered it via an oil-in-water nanoemulsion.
Freshly prepared K/nanoemulsion exhibited greater bactericidal
properties than freely suspended bacteriophage. The emulsions
containing the K phage killed cells of three different strains of
S. aureus. Similar observations were obtained for preparations
that were stored at room temperature and at 4◦C, for up
to 10 days. It was observed that bacteriophage activity was
enhanced when it was delivered via nanoemulsions. Tablets and
powders containing phages may ensure the phage titer and
its stability in low humidity conditions (Schade and Caroline,
1944c).
The shelf life of phage preparations should be monitored, as
phages differ in their titer’s stability under storage conditions,
and its persistence depends on suspended media as well as on
different physical and chemical external conditions (Jon´czyk
et al., 2011). A good candidate for phage therapy is a phage
that can easily propagate in both laboratory and industrial
conditions and is characterized by stability in storage conditions.
For some phages storage in lysate form at 4◦C is required, as no
significant loss of its titer is observed (Ackermann et al., 2004).
For other phages better conditions that allow titer stability to
be maintained may be freezing at −80◦C with the addition of
glycerol or freeze-drying. Golec et al. (2011) offered a reliable
method of preservation of tailed phages. It involves storage of
phages in the DNA form frozen inside the infected bacterial
cells at −80◦C without observing any significant decrease in
phage and host viability. The authors suggested that this method
may be useful for newly isolated phages that have an unknown
structure and biology and whose propagation conditions have
not been determined and optimized. They also recommend this
method as suitable for phage preservation. Puapermpoonsiri
et al. (2010) indicated that the secondary drying cycle following
lyophilization is most important for maintaining phage stability.
Phages active against Pseudomonas aeruginosa and S. aureus were
encapsulated into biodegradable microspheres (for inhalation)
based on emulsification and freeze-drying, and it was observed
that only a partial loss of phage lytic activity took place, which
may result from the exposure of the phage particles to the water-
dichloromethane interface, with the lyophilization process itself
having little effect (Puapermpoonsiri et al., 2009). Also, Alfahdel
et al. (2011) used S. aureus phage lyophilization in a viscous
solution of 1–2% (w/v) hydroxypropyl methylcellulose (HPMC)
with/without the addition of 1% (w/v) mannitol, yielding nasal
inserts composed of a highly porous leaflet-like matrix. Phages
were homogeneously distributed in the dried matrix. Their titers
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decreased 10-fold following lyophilization to 108 pfu per insert;
and further 100- to 1000-fold loss of pfu was observed during
6–12 months of storage at 4◦C. It is possible to add substances,
e.g., albumin, salts, or gelatin, to improve stability; but in the case
of phages in pharmaceutical application it may be problematic
(Gill and Hyman, 2010). Tovkach et al. (2012) prepared an
Erwiniophage ZF40 suspension with the addition of a magnesium
and gelatin STMF buffer which ensured the stability in long-term
preservation of unstable enterobacterial phages (+4 to −2◦C).
The authors mentioned that the possible problems with long-
term storage may be the result of phage virions’ or DNA structural
instability. Schade and Caroline (1944b,c) tested the influence
of lyophilization on phage stability. They observed that that
addition of, for example, yeast extract, lecithin, and raw egg
white, protected dysentery phage Sh-1, promoting the stability
of this sensitive phage during lyophilization. Interestingly, the
dysentery phage was protected against damage that could be
the result of lyophilization, and obtained powders were stable
during 12 months of storage over a desiccant at 37◦C (Schade
and Caroline, 1944a). Also phages active against S. aureus,
including MRSA strains, were lyophilized with the presence of
different stabilizers: sucrose, trehalose, mannitol, and glycine,
polyvinylpyrrolidone and PEG 6000 (polyethylene glycol) at
different concentrations (Merabishvili et al., 2013). Trehalose and
sucrose (0.5 M) were found to be the best additives protecting the
ISP phage, whose titer dropped by 1 log after lyophilization and
by another one after being stored in powder form for 37 months
at 4◦C.
Fortier and Moineau (2009) stated that lyophilization is a
more effective method to preserve phage stability than storage
in a solution, and lyophilized phages had higher heat stability
and were resistant to drying. As they observed, phage protective
action was provided in egg yolk. Other researchers observed that
storing the BFC-1 phage cocktail for 12 months at 4◦C, did not
cause the observed loss of stability (Merabishvili et al., 2009).
Importantly, inactivation of phage particles may occur before
reaching the site of infection. This situation should be possible
to avoid; therefore the initial dose and the route of phage
administration should enable them to circulate, achieve the
infection site and multiply there as long as pathogenic bacteria
are present (Gill and Young, 2011). However, suspensions of
phages that exceed 1013 pfu/ml seem to be difficult to obtain since
concentrated suspensions become too viscous (Nilsson, 2014).
Phage preparations that are used as therapeutics may contain
only one phage or be a cocktail consisting of two or more phages.
The latter type of preparation’s composition may prevent the
occurrence of cross-resistance, and, based on this phenomenon,
a bacterium which is resistant to one phage may remain sensitive
to another, and cocktails that contain phages using different
receptors for binding to bacteria may be a better solution for
eliminating the development of resistance in bacteria (Gill and
Hyman, 2010). Some changes in lytic patterns of patients’ strains
isolated during the course of phage therapy may be observed. It
may be due to instability and heterogeneity of bacterial strains as
well as different bio- and serotypes of bacteria or changing phage
receptors. According to Chan and Abedon (2012), the treatment
of infections caused by antibiotic-resistant bacteria seems to be
more effective when a phage cocktail is used, compared with
single phage efficacy.
LIMITATIONS OF PHAGE
PROCUREMENT FOR THERAPEUTIC
PURPOSES
The most important factor for effective use of phages as
therapeutics is the widest possible knowledge (Goodridge, 2010)
regarding biology of phages, their individual properties and
stability in different forms of available preparations (both lysates
and purified preparations). There are opinions that phage
treatment may induce the production of antiphage antibodies
and this may limit the phage antibacterial activity (Sulakvelidze
et al., 2001). Moreover, it is possible that bacteria may develop
resistance to phages. The next limitation is the lack of legislative
solutions adapted to broad use of bacteriophages to combat
antibiotic-resistant bacteria.
The presence of phages of a wide host range in the collections,
on one hand, allows the number of phages needed in a collection
to be reduced, and on the other hand, it offers the opportunity to
increase the probability of finding phages active against emerging
drug-resistant bacterial strains (Mirzaei and Nilsson, 2015). The
phage searching and isolation procedure should be designed in
such a way as to prevent possible treatment failure resulting from
wrong phage selection (Gill and Hyman, 2010).
Clear lysis zones observed on a bacterial lawn are most often
the result of phages’ lytic activity. Sometimes, it is possible for
a phage preparation to contain a factor that causes lysis but it
is not directly connected with phages’ lytic activity (Hyman and
Abedon, 2010). The agents responsible for the observed effect
could be bacteriocins, endolysins (that may cause lysis from
without). Additionally, abortive infection can cause bacterial
death without the release of new phage progeny. Interestingly,
filamentous phages form plaques, but they do not lead to the
lysis of bacterial cells (Gill and Hyman, 2010). Also Bdellovibrio
bacteria can form plaques (Hobley et al., 2006).
It is extremely important to keep in mind that there are
differences between phages themselves, and the type of their
isolation, tested material, and thus the type of procedure during
phage propagation should be adjusted to an individual phage and
should depend on the type of host bacteria in which phages are
propagated (Mattila et al., 2015). Sometimes it is not possible
to detect any plaques on the bacterial lawn. The reason for
this phenomenon may be that the bacterial host is insensitive
to the phage, and it does not indicate that there is no phage
in the sample but that the wrong bacteria were chosen (Gill
and Young, 2011) or that phage particles could disintegrate
(Gill and Hyman, 2010). One of the isolation limitations may
result from the differences in propagation ability of phages under
experimental conditions or from the inability to isolate phages
which are present in the sample (Hendrix, 2002). Bacteria that are
present in environmental samples are unculturable (we cannot
isolate them, or we do not know the culture requirements)
in laboratory conditions with commonly available equipment
and methods, and therefore we are able to isolate only a small
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number of phages occurring in these sources. Cultures used
in the search for phages occurring in water samples should
be incubated at 25◦C rather than 37◦C. Interestingly, it is
of great importance to adjust proper culture conditions to a
particular bacterial host’s requirements. Procurement of phages
generally may seem to be easy, but matching them for therapeutic
purposes should be adjusted to individual phage properties.
Other limitations may be due to a large number of genetic
changes in bacterial and phage strains. This phenomenon may
be in part a result of the acquisition of resistance to phages by
bacteria.
Phage virions within the mammalian body are exposed to
factors that may cause their inactivation. Contact with the acidic
gastric pH (Verthé et al., 2004), alkaline bile salts (Ma et al., 2008),
antibodies (Keller and Traub, 1974) and phagocytes, as well as the
toxicity of urea, may result in the loss of their lytic activity. In
order to avoid adverse factors, searching for improved methods
of administration and formulations for new forms that reduce
the exposure of phage to destructive conditions is desirable. For
example, the encapsulation of phages may enable phage particles
to retain the activity in unfavorable conditions (Dini et al., 2012;
Colom et al., 2015).
Therapeutic phages are currently applied in the form of lysates
or purified preparations, and they cannot be toxic (Skurnik and
Strauch, 2006; Skurnik et al., 2007). Due to the necessity to keep
the final preparations safe, it is essential that the media used
for phage cultivation and propagation are definitely free from
such dangerous contaminants as prions, viruses and allergens
(Goodridge and Abedon, 2008).
In order to prevent an anaphylactic reaction in response
to bacterial components, such as endotoxins (which may be a
component of the phage lysate), some investigators recommend
the use of purified preparations (Skurnik and Strauch, 2006; Loc-
Carrillo and Abedon, 2011). However, while it is thought that
the staphylococcal phage lysates stimulate the body’s immune
response, purified preparations may show immunosuppressive
activity (Górski et al., 2012). Purification of phage preparations
of bacterial endotoxins is becoming more effective. Endotoxin
levels in preparations for intravenous use should not exceed 5
endotoxin units (EU 1≈ 100 pg) per kilogram of body weight per
hour (Wanninger and Artz, 2009). The most common method
uses isopycnic density gradient centrifugation. Sometimes this
method may be problematic – phage particles may be damaged
by high salt concentrations (Gill and Young, 2011). There
are methods, e.g., ion exchange chromatography or affinity
chromatography (Os´lizło et al., 2011; Narasimhaiah et al., 2013),
which allow one to obtain purified preparations with reduced
endotoxin content. Other methods used for phage purification
may be cesium chloride (CsCl) gradient centrifugation or sucrose
gradient (Kleiner et al., 2015). The yield of phages using the CsCl
method is low, and some phages may be lost due to aggregation
or damage of virions. High performance liquid chromatography
(HPLC) may also be applied successfully to concentrate and
purify tailed phages (Adriaenssens et al., 2012). Both the
methods of staphylococcal phage purification (P391328) and
the method of obtaining bacteriophage preparations containing
trace amounts of endotoxins (P382800; US 20100227376 A1)
have been used in our laboratory under patent protection. For
phage purification, Merabishvili et al. (2009) recommended the
use of the Endotrap blue chromatographic column that binds
endotoxins.
MODIFIED PHAGES
Apart from isolating naturally occurring phages from
environmental samples, it is possible to obtain genetically
modified phages (by recombination of phage genomes, site-
directed mutagenesis, selection of spontaneous mutants or phage
display methods). These methods offer a great therapeutic tool
for dealing with the challenges of phage therapy (Moradpour
and Ghasemian, 2011; Chhibber and Kumari, 2012; Da˛browska
et al., 2014). Modified phages may be deplated of undesired
properties, may have changed specificity or improved therapeutic
potential, as e.g., phages that have dual activity – antitumor and
bactericidal – without an observable reduction in antimicrobial
activity (Da˛browska et al., 2014). These findings open new
possibilities for the use of phage therapy.
The discovery of bacterial adaptive immunity system,
CRISPR/Cas (Clustered Regularly Interspaced Palindromic
Repeats [CRISPR]/CRISPR-associated [Cas]) systems, has
opened new possibilities in the design of a genetic load that can
be delivered by bacteriophages. In nature, bacteria can acquire
resistance to a bacteriophage by the incorporation of the genome
fragment of this bacteriophage as a spacer between repeats in
the CRISPR locus (Szczepankowska, 2012). In the case of the
CRISPR/Cas systems of type II, small CRISPR RNAs (crRNAs)
produced by the processing of CRISPR locus transcripts serve
to guide a nucleolytic enzyme to target invading phage or
other DNA molecules, if they are only complementary to them.
The CRISPR/Cas systems were also found in some phages
(Hargreaves et al., 2014; Zheng et al., 2016). A CRISPR/Cas
system that is encoded by a virulent V. cholerae phage is used
to destroy the DNA of its host chromosomal island, which
excises from the chromosome in response to phage infection,
circularizes and interferes with phage development (Seed et al.,
2013). This natural system provides a proof of the concept that
phage-mediated delivery of CRISPR/Cas-encoded RNA-guided
nucleases (RGNs) is an efficient way to target bacterial DNA in
a sequence specific manner. Indeed staphylococcal φMN1phage
particles packed with engineered phagemid DNA carrying
CRISPR/Cas with spacers targeting certain S. aureus virulence
genes killed virulent, but not avirulent S. aureus (Bikard et al.,
2014). They could also reduce the number of virulent S. aureus
strain cells on a skin of infected mice. Modified phages with
multiple varying CRISPR spacers were effective in destruction of
multiple DNA targets in the infected bacterial cell.
Phages of changed properties may be also obtained by
chemical modifications. Modifications of phage particles by
attaching monomethoxy-polyethylene glycol (mPEG) to proteins
caused the phage to become less immunogenic. The PEGylated
phage caused a decrease in the level of cytokines such as IFN-γ
and IL-6 in both the non-immunized and the phage immunized
mice (Kim et al., 2008). The modified phage particles were
Frontiers in Microbiology | www.frontiersin.org 9 August 2016 | Volume 7 | Article 1177
fmicb-07-01177 August 10, 2016 Time: 18:1 # 10
Weber-Da˛browska et al. Phage Selection for Phage Therapy
characterized by a longer half-life in the organism, which may
be of practical importance in enhancing the effectiveness of
phage therapy. Our recent hypothesis suggests that it might
be possible to obtain modified phages with homing peptides
that enable phage localization in infected tissues (Górski
et al., 2015). Taken together, all kinds of phage modifications
open new possibilities for the use phages in antibacterial
therapies.
CONCLUDING REMARKS
Phage therapy offers a real chance for patients suffering from
infections caused by antibiotic-resistant bacteria. Widening our
knowledge about phage biology, their individual properties and
stability in different forms of available preparations offers the
most significant prospect for effective application of phages as
therapeutics (Goodridge, 2010).
Phage searching and isolation procedures should be adjusted
to the type of bacterial strain being the host of the phage, which
would also prevent treatment failures that may lead to phage
misselection. Phage preparations intended for treating infections
in humans should be safe, sterile and endotoxin-free. What
is more, the methods of administration and formulations for
new forms that reduce the exposure of phages to destructive
conditions should be improved. Genetically modified phages with
broader activity may be obtained, and it is possible to shape
their activity depending on the therapeutic needs. The progress
in the knowledge about phage genomics, immunobiology and
experimental therapy in animals and in humans suggest that
phages could become the antibacterial drugs of the 21st century.
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